Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.26 is 13% above its 5-year average of 4.66, around the middle of its 5-year range (3.18–7.74).
As of the fiscal period ended Tuesday, June 30, 2026. 20.18% above its 12-month average of 4.38.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.26.
QUICK RATIO (ACID-TEST)
5.26
QUICK RATIO (ACID-TEST) AVG TTM
4.38
QUICK RATIO (ACID-TEST) AVG 3Y
3.56
QUICK RATIO (ACID-TEST) AVG 5Y
4.66
QUICK RATIO (ACID-TEST) AVG 10Y
4.92
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.18%
CURRENT VS 3Y AVG
+47.87%
CURRENT VS 5Y AVG
+12.77%
CURRENT VS 10Y AVG
+6.95%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.11
median of 688 covered companies
CURRENT VS SECTOR MEDIAN
+69.14%
vs the sector median at left
Alector, Inc.
Market Cap
$212.06M
Quick Ratio (Acid-Test)
5.26
TTM Avg
4.38
3Y Avg
3.56
5Y Avg
4.66
Market Cap
$208.00M
Quick Ratio (Acid-Test)
2.45
TTM Avg
2.08
3Y Avg
1.84
5Y Avg
1.77
Market Cap
$214.19M
Quick Ratio (Acid-Test)
344.31
TTM Avg
177.51
3Y Avg
95.13
5Y Avg
76.52
Market Cap
$215.44M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$215.58M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$216.01M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$217.48M
Quick Ratio (Acid-Test)
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$202.90M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$225.64M
Quick Ratio (Acid-Test)
21.96
TTM Avg
18.45
3Y Avg
17.11
5Y Avg
21.15
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alector, Inc. (ALEC) | $212.06M | 5.26 | 4.38 | 3.56 | 4.66 |
| Pro-Dex, Inc. (PDEX)vs › | $208.00M | 2.45 | 2.08 | 1.84 | 1.77 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.19M | 344.31 | 177.51 | 95.13 | 76.52 |
| Niagen Bioscience Inc (NAGE)vs › | $215.44M | 5.13 | 3.45 | 2.59 | 2.27 |
| Compugen Ltd. (CGEN)vs › | $215.58M | 5.72 | 5.91 | 5.85 | 7.15 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $216.01M | 5.36 | 6.17 | 11.50 | 11.99 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $217.48M | 4.07 | 3.65 | 6.88 | 10.38 |
| Electra Therapeutics Inc. (ETRA)vs › | $202.90M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $225.64M | 21.96 | 18.45 | 17.11 | 21.15 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $194.13M | 7.90 | 9.91 | 10.86 | 18.34 |
Quick Ratio
5.26
Excludes inventory
Current Ratio
5.26
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.26 |
| 2026-03-31 | 5.25 |
| 2025-12-31 | 3.83 |
| 2025-09-30 | 3.76 |
| 2025-06-30 | 3.78 |
| 2025-03-31 | 3.34 |
| 2024-12-31 | 3.40 |
| 2024-09-30 | 3.29 |
| 2024-06-30 | 3.52 |
| 2024-03-31 | 3.53 |
| 2023-12-31 | 3.18 |
| 2023-09-30 | 3.95 |
| 2023-06-30 | 4.90 |
| 2023-03-31 | 6.91 |
| 2022-12-31 | 7.74 |
| 2022-09-30 | 4.82 |
| 2022-06-30 | 5.54 |
| 2022-03-31 | 6.24 |
| 2021-12-31 | 5.37 |
| 2021-09-30 | 5.93 |
| 2021-06-30 | 4.43 |
| 2021-03-31 | 5.85 |
| 2020-12-31 | 6.19 |
| 2020-09-30 | 6.61 |
| 2020-06-30 | 7.75 |
| 2020-03-31 | 7.75 |
| 2019-12-31 | 5.77 |
| 2019-09-30 | 6.56 |
| 2019-06-30 | 6.18 |
| 2019-03-31 | 7.92 |
| 2018-12-31 | 22.48 |
| 2018-09-30 | 7.62 |
| 2018-06-30 | 7.32 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 8.50 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
